CPT-11 and L-OHP combination versus alternated combination of LV5FU2+CPT-11/LV5FU2+L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results

被引：1
|
作者：
Becouam, Y
Mousseau, M
Gamelin, E
Coudert, B
Marceau-Suissa, J
Bekradda, M
机构：
[1] Inst Bergonie Bordeaux, Bordeaux, France
[2] CHU Grenoble, F-38043 Grenoble, France
[3] Ctr Paul Papin, Angers, France
[4] Ctr F Leclerc, Dijon, France
[5] Rhone Poulenc Rorer, Montrouge, France
[6] C&AC Kremlin Bicetre, Le Kremlin Bicetre, France
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)80652-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：S71 / S71
页数：1
相关论文
共 50 条
  • [31] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [32] A dose finding study of biweekly administration of irinotecan (CPT-11), 5-fluorouracil (5-FU) and levofolinic acid (I-LV) in colorectal cancer
    Casaretti, R
    Catalano, G
    Comella, P
    De Vita, F
    Avallone, V
    Gravina, A
    Orditura, M
    Comis, S
    Faranda, A
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 68 - 68
  • [33] CPT-11与5-Fu/LV方案治疗胃癌术后转移的临床价值
    张勇超
    中国肿瘤临床与康复, 2010, 17 (06) : 511 - 512
  • [34] L-OHP联合5-FU-LV与HCPT联合5-FU-LV化疗方案对可切除胃癌术后预后的研究
    徐东
    郭建平
    于振国
    中国现代普通外科进展, 2019, 22 (02) : 117 - 120
  • [35] Consistent safety and efficacy results in 2 study populations treated with irinotecan (CPT-11) for metastatic colorectal cancer (MCRC) resistant to 5-FU
    Guimbaud, R
    Bugat, R
    VanCutsem, E
    Mignard, D
    Mahjoubi, M
    Canal, P
    Blanc, C
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 736 - 736
  • [36] A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC AccordO2/FFCD9802).
    Ychou, M
    Raoul, JL
    Douillard, JY
    Bugat, R
    Mineur, L
    Viret, F
    Becouarn, Y
    Bouche, O
    Jacob, JH
    Gourgou-Bourgade, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 246S - 246S
  • [37] 5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayar, C.
    Piedbois, P.
    Culine, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Irinotecan (CPT-11) in advanced colorectal cancer patients with progression after therapy with 5-FU.
    Mendez, M
    Salud, A
    García, C
    Navalón, M
    España, P
    Cruz, JJ
    Diz, P
    del Val, G
    del Prado, M
    ANNALS OF ONCOLOGY, 2000, 11 : 56 - 56
  • [39] A phase II study of neoadjuvant irinatecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for resectable liver metastases from colorectal cancer.
    Bathe, OF
    Ernst, S
    Sutherland, F
    Dixon, E
    Koppel, J
    Butts, C
    Bigam, D
    Ruether, D
    Walley, B
    Dowden, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 286S - 286S
  • [40] Folfiri (CPT11/LV5FU2) and folfox4 (oxaliplatin/LV5FU2): Two safety regimens in elderly fit patients with metastatic colorectal cancer (MCRC).
    Nardi, M
    Mare, M
    Zavettieri, M
    Raffaele, M
    Panuccio, V
    Azzarello, D
    Cortese, C
    Del Medico, P
    Falzea, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 296S - 296S
12345